The Experts below are selected from a list of 10623 Experts worldwide ranked by ideXlab platform

Susan L Mcelroy - One of the best experts on this subject based on the ideXlab platform.

  • lisdexamfetamine in pediatric Binge Eating Disorder a retrospective chart review
    Clinical Neuropharmacology, 2019
    Co-Authors: Anna I Guerdjikova, Thomas J Blom, Nicole Mori, Abigail Matthews, Tracy Cummings, Leah L Casuto, Susan L Mcelroy
    Abstract:

    Objectives The purpose of this retrospective chart review was to evaluate lisdexamfetamine dimesylate (LDX) in the treatment of pediatric Binge Eating Disorder (BED). Methods We examined the clinical records of 25 patients, 12 to 19 years of age, who were prescribed LDX and had a diagnosis of BED between 2014 and 2017. Results Binge Eating Disorder in adolescents was highly comorbid with attention deficit hyperactivity Disorder, mood and anxiety Disorders, and severe obesity. Fifteen participants reported some level of improvement of their BED symptoms with LDX treatment. Posttreatment body mass index (BMI) percentile was not significantly reduced, and all but 2 participants remained in their same BMI classification. Lisdexamfetamine dimesylate treatment duration was not associated with change in BMI percentile, and the medication was well tolerated. Conclusions Lisdexamfetamine dimesylate may have clinical utility for BED in adolescents, but randomized, placebo-controlled studies of its efficacy, tolerability, and safety in this population are needed.

  • Update on Binge Eating Disorder.
    The Medical clinics of North America, 2019
    Co-Authors: Anna I Guerdjikova, Nicole Mori, Leah L Casuto, Susan L Mcelroy
    Abstract:

    Binge Eating Disorder (BED) is the most common Eating Disorder and an important public health problem. Lifetime prevalence of BED in the United States is 2.6%. In contrast to other Eating Disorders, the female to male ratio in BED is more balanced. BED co-occurs with a plethora of psychiatric Disorders, most commonly mood and anxiety Disorders. BED is also associated with obesity and its numerous complications. Although BED is similar in men and women in presentation and treatment outcomes, there are some key neurobiological differences that should be taken in consideration when personalizing treatment.

  • Binge Eating Disorder
    The Psychiatric clinics of North America, 2017
    Co-Authors: Anna I Guerdjikova, Nicole Mori, Leah L Casuto, Susan L Mcelroy
    Abstract:

    Binge Eating Disorder (BED) is the most common Eating Disorder and an important public health problem. Lifetime prevalence of BED in the United States is 2.6%. In contrast to other Eating Disorders, the female to male ratio in BED is more balanced. BED co-occurs with a plethora of psychiatric Disorders, most commonly mood and anxiety Disorders. BED is also associated with obesity and its numerous complications. Although BED is similar in men and women in presentation and treatment outcomes, there are some key neurobiological differences that should be taken in consideration when personalizing treatment.

  • Medical comorbidity of Binge Eating Disorder.
    Eating and weight disorders : EWD, 2016
    Co-Authors: Pablo Olguin, Anna I Guerdjikova, Paul E Keck, Manuel Fuentes, Guillermo Gabler, Susan L Mcelroy
    Abstract:

    Purpose To gain further understanding of the general medical comorbidity of Binge Eating Disorder (BED) beyond its association with obesity.

  • successful treatment of Binge Eating Disorder with combination phentermine topiramate extended release
    The Primary Care Companion To The Journal of Clinical Psychiatry, 2015
    Co-Authors: Anna I Guerdjikova, Angela Fitch, Susan L Mcelroy
    Abstract:

    To the Editor: Phentermine/topiramate extended release is a novel medication approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults. To our knowledge, phentermine/topiramate extended release has not yet been evaluated in Binge Eating Disorder, which often co-occurs with obesity. We therefore present 2 patients with Binge Eating Disorder and obesity who experienced cessation of Binge-Eating behaviors and clinically significant weight loss with phentermine/topiramate extended release.

Anna I Guerdjikova - One of the best experts on this subject based on the ideXlab platform.

  • lisdexamfetamine in pediatric Binge Eating Disorder a retrospective chart review
    Clinical Neuropharmacology, 2019
    Co-Authors: Anna I Guerdjikova, Thomas J Blom, Nicole Mori, Abigail Matthews, Tracy Cummings, Leah L Casuto, Susan L Mcelroy
    Abstract:

    Objectives The purpose of this retrospective chart review was to evaluate lisdexamfetamine dimesylate (LDX) in the treatment of pediatric Binge Eating Disorder (BED). Methods We examined the clinical records of 25 patients, 12 to 19 years of age, who were prescribed LDX and had a diagnosis of BED between 2014 and 2017. Results Binge Eating Disorder in adolescents was highly comorbid with attention deficit hyperactivity Disorder, mood and anxiety Disorders, and severe obesity. Fifteen participants reported some level of improvement of their BED symptoms with LDX treatment. Posttreatment body mass index (BMI) percentile was not significantly reduced, and all but 2 participants remained in their same BMI classification. Lisdexamfetamine dimesylate treatment duration was not associated with change in BMI percentile, and the medication was well tolerated. Conclusions Lisdexamfetamine dimesylate may have clinical utility for BED in adolescents, but randomized, placebo-controlled studies of its efficacy, tolerability, and safety in this population are needed.

  • Update on Binge Eating Disorder.
    The Medical clinics of North America, 2019
    Co-Authors: Anna I Guerdjikova, Nicole Mori, Leah L Casuto, Susan L Mcelroy
    Abstract:

    Binge Eating Disorder (BED) is the most common Eating Disorder and an important public health problem. Lifetime prevalence of BED in the United States is 2.6%. In contrast to other Eating Disorders, the female to male ratio in BED is more balanced. BED co-occurs with a plethora of psychiatric Disorders, most commonly mood and anxiety Disorders. BED is also associated with obesity and its numerous complications. Although BED is similar in men and women in presentation and treatment outcomes, there are some key neurobiological differences that should be taken in consideration when personalizing treatment.

  • Binge Eating Disorder
    The Psychiatric clinics of North America, 2017
    Co-Authors: Anna I Guerdjikova, Nicole Mori, Leah L Casuto, Susan L Mcelroy
    Abstract:

    Binge Eating Disorder (BED) is the most common Eating Disorder and an important public health problem. Lifetime prevalence of BED in the United States is 2.6%. In contrast to other Eating Disorders, the female to male ratio in BED is more balanced. BED co-occurs with a plethora of psychiatric Disorders, most commonly mood and anxiety Disorders. BED is also associated with obesity and its numerous complications. Although BED is similar in men and women in presentation and treatment outcomes, there are some key neurobiological differences that should be taken in consideration when personalizing treatment.

  • Medical comorbidity of Binge Eating Disorder.
    Eating and weight disorders : EWD, 2016
    Co-Authors: Pablo Olguin, Anna I Guerdjikova, Paul E Keck, Manuel Fuentes, Guillermo Gabler, Susan L Mcelroy
    Abstract:

    Purpose To gain further understanding of the general medical comorbidity of Binge Eating Disorder (BED) beyond its association with obesity.

  • successful treatment of Binge Eating Disorder with combination phentermine topiramate extended release
    The Primary Care Companion To The Journal of Clinical Psychiatry, 2015
    Co-Authors: Anna I Guerdjikova, Angela Fitch, Susan L Mcelroy
    Abstract:

    To the Editor: Phentermine/topiramate extended release is a novel medication approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults. To our knowledge, phentermine/topiramate extended release has not yet been evaluated in Binge Eating Disorder, which often co-occurs with obesity. We therefore present 2 patients with Binge Eating Disorder and obesity who experienced cessation of Binge-Eating behaviors and clinically significant weight loss with phentermine/topiramate extended release.

Angela Fitch - One of the best experts on this subject based on the ideXlab platform.

James I. Hudson - One of the best experts on this subject based on the ideXlab platform.

  • by how much will the proposed new dsm 5 criteria increase the prevalence of Binge Eating Disorder
    International Journal of Eating Disorders, 2012
    Co-Authors: Harrison G. Pope, Justine K. Lalonde, James I. Hudson, Caitlin E Coit
    Abstract:

    Objective: To estimate how much the prevalence of Binge Eating Disorder will increase under the new proposed DSM-5 criteria, which relax the requirements for the frequency and duration of Eating Binges. Method: Interview data from a nonclinical sample of 888 first-degree relatives who had participated in a family study of Binge Eating Disorder were analyzed. The probands in this study (not included in this analysis) had been selected to either have Binge Eating Disorder or no history of Eating Binges. Results: The increase in the prevalence of Binge Eating Disorder using the proposed DSM-5 criteria relative to the DSM-IV criteria was 2.9% in women and 3.0% men for lifetime prevalence, and 7.7% in women and 0% in men for the point prevalence. Discussion: Changes in frequency and duration of Binge episodes proposed for DSM-5 will likely have only a minimal effect on the prevalence of Binge Eating Disorder. © 2010 by Wiley Periodicals, Inc. (Int J Eat Disord 2012)

  • sodium oxybate in the treatment of Binge Eating Disorder an open label prospective study
    International Journal of Eating Disorders, 2011
    Co-Authors: Susan L Mcelroy, Anna I Guerdjikova, Nicole Mori, Erin L Winstanley, Anne M Omelia, Paul E Keck, James I. Hudson
    Abstract:

    Objective: To assess preliminarily the effectiveness of sodium oxybate in Binge Eating Disorder. Method: This was an open-label, prospective, 16-week, flexible dose study of sodium oxybate in Binge Eating Disorder. The primary outcome was Binge Eating episode frequency. Results: Twelve individuals received sodium oxybate, 10 completed at least one postbaseline evaluation, and five completed the study. Mean dose at endpoint was 7.1 (2.0) g/day. Sodium oxybate was associated with significant reductions in frequency of Binge days and Binge episodes, as well as measures of clinical severity, Eating pathology, obsessive-compulsive symptoms, food cravings, body mass index, and body weight. Nine participants had remission of Binge Eating and five lost 5% of their baseline weight; all five of the latter participants had remission of Binge Eating. Discussion: In this open-label trial, sodium oxybate was effective in Binge Eating Disorder, but associated with high a discontinuation rate. V C 2010 by Wiley

  • Binge Eating Disorder: A Stable Syndrome
    The American journal of psychiatry, 2006
    Co-Authors: Harrison G. Pope, Susan L Mcelroy, Cynthia M. Bulik, Justine K. Lalonde, Lindsay J. Pindyck, Timothy Walsh, Norman E. Rosenthal, James I. Hudson
    Abstract:

    Objective: This study assessed the stability of Binge Eating Disorder in a community sample. Method: The authors interviewed 888 first-degree relatives of 300 overweight or obese probands (150 with Binge Eating Disorder and 150 with no lifetime Eating Disorder) who were recruited during a family study. They compared the total duration of illness among relatives with lifetime diagnoses of Binge Eating Disorder (N=131), bulimia nervosa (N=17), and anorexia nervosa (N=18). Results: The mean lifetime duration of Binge Eating Disorder was 14.4 years (SD=13.9), significantly longer than for either bulimia nervosa (mean=5.8 years, SD=9.1) or anorexia nervosa (mean=5.9 years, SD=7.4). These differences changed little when analysis was restricted to female relatives or to relatives of the probands with no lifetime Eating Disorder. Conclusions: These findings suggest that Binge Eating Disorder is at least as chronic as the well-validated Disorders anorexia nervosa and bulimia nervosa and likely represents a stable ...

  • Binge Eating Disorder as a distinct familial phenotype in obese individuals
    Archives of General Psychiatry, 2006
    Co-Authors: James I. Hudson, Susan L Mcelroy, Cynthia M. Bulik, Justine K. Lalonde, Lindsay J. Pindyck, Scott J. Crow, Judith M Berry, Nan M Laird, Ming T Tsuang
    Abstract:

    Context Binge-Eating Disorder (BED)—a syndrome that only recently has attracted scientific attention—is often seen in obese individuals, especially those with severe obesity. However, it remains unclear whether BED represents an etiologically distinct behavioral phenotype of obesity or simply a nonspecific Eating pattern sometimes seen in obese individuals. Objective To test whether BED aggregates in families independently of obesity, and if so, whether familial factors for BED also independently increase the risk of obesity. Design, Patients, and Setting Blinded family interview study of overweight or obese probands with (n = 150) and without (n = 150) BED, and their first-degree relatives (n = 888) in a community setting evaluated between October 2002 and July 2004. Main Outcome Measures Lifetime diagnosis of BED; current and highest lifetime body mass index (calculated as the weight in kilograms divided by the square of the height in meters). Results Binge-Eating Disorder aggregated strongly in families independently of obesity (odds ratio, 2.2; 95% confidence interval, 1.4-3.6; P P  = .002). Conclusions Binge-Eating Disorder is a familial Disorder caused in part by factors distinct from other familial factors for obesity. Furthermore, these BED-specific familial factors may independently increase the risk of obesity, especially severe obesity. It follows that targeted interventions capable of preventing or trEating traits influenced by these BED-specific familial factors could reduce the public health burden of obesity.

  • Antidepressant treatment of Binge-Eating Disorder: research findings and clinical guidelines.
    The Journal of clinical psychiatry, 1996
    Co-Authors: James I. Hudson, W. P. Carter, Harrison G. Pope
    Abstract:

    Binge-Eating Disorder, characterized by recurrent Eating Binges without purging, affects a large number of individuals, especially among participants in weight loss programs. Recent studies have suggested that antidepressants, particularly serotonin selective reuptake inhibitors, may be effective in the treatment of Binge-Eating Disorder. This paper reviews the findings of these studies and offers clinical guidelines for the use of antidepressants in Binge-Eating Disorder.

Michael J. Devlin - One of the best experts on this subject based on the ideXlab platform.

  • Cognitive behavioral therapy for the treatment of Binge Eating Disorder: what constitutes success?
    The American journal of psychiatry, 2000
    Co-Authors: Juli A. Goldfein, Michael J. Devlin, Robert L Spitzer
    Abstract:

    In the historical development of psychiatric nosology, as in the rest of medicine, more severe Disorders tend to be recognized before Disorders with milder symptom profiles. Thus, psychiatric classifications recognized schizophrenia and melancholia before schizotypal personality Disorder and dysthymia. So, too, with the classification of Eating Disorders; anorexia nervosa, which may result in death, was recognized many years before bulimia nervosa. The most recent addition to the psychiatric classification of Eating Disorders is “Binge Eating Disorder.” The diagnosis of Binge Eating Disorder is given to the many obese individuals who are distressed by recurrent Binge Eating, yet do not regularly engage in the compensatory behavior (e.g., vomiting or use of laxatives) that is seen in individuals with bulimia nervosa. Although Binge Eating Disorder is not an official DSM-IV diagnosis, a variety of studies support its validity (1–4). A description of the Disorder and its diagnostic criteria appear in DSM-IV Appendix B, titled “Criteria Sets and Axes Provided for Further Study.” Binge Eating Disorder is common among study groups drawn from weight-control programs (15%–50%), which show women are approximately 1.5 times more likely to have the Disorder than men. In nonpatient community samples, a prevalence rate of 1%–4% has been reported (1, 3). Typically, the Disorder begins in late adolescence or in the early 20s, often after weight loss from severe dieting. Common associated features include marked fluctuations in weight over time and a history of depression, anxiety, low self-esteem, somatic concern, and interpersonal sensitivity. Along with the recognition of Binge Eating Disorder and its clinical features, there has been increasing interest in developing effective treatments for the Disorder. Several studies have examined the relative efficacy of psychotherapeutic and psychopharmacological approaches (5). This case conference illustrates some of the challenges and rewards involved in the treatment of a patient with Binge Eating Disorder.

  • Assessment and treatment of Binge-Eating Disorder
    The Psychiatric clinics of North America, 1996
    Co-Authors: Michael J. Devlin
    Abstract:

    Previous articles in this issue have described the characteristics and treatment of the classic Eating Disorders anorexia nervosa and bulimia nervosa. Binge-Eating Disorder, in contrast, is a newly recognized Eating Disorder characterized by episodic uncontrolled consumption of large amounts of food in the absence of the inappropriate compensatory methods that characterize bulimia nervosa, including vomiting, laxative abuse, fasting, or excessive exercise following an Eating Binge. The provisional criteria for Binge Eating Disorder, which have been included in the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV, Appendix B: Criteria Sets and Axes Provided for Further Study and are summarized here in Table 1, specify that the individual must experience significant distress related to Binge Eating and must endorse several behavioral indicators of loss of control. Although the criteria do not specify that the affected individual must be overweight, most patients currently presenting for treatment for Binge-Eating Disorder are overweight, and this article therefore focuses on overweight Binge-Eating Disorder patients. The following patient is typical of a number of patients who have in recent years presented to our Eating Disorders Clinic requesting treatment: Ms. A. was a 39-year-old single advertising executive who lived alone in an affluent urban neighborhood. She presented to our clinic for treatment of Binge Eating since age 10. At the time of presentation, she weighed 194.5 lb at a height of 5 feet and 5.25 inches (body mass index [BMI] 32.1). She had a history of frequent dieting and estimated that she had been dieting for about three quarters of her adult life. Her most recent major diet took place over a 3-month period 2 years prior to presentation when she lost from 175 down to 140 lb on a liquid fast program, but within 6 months began to regain the weight. Her weight of 194.5 lb on presentation was her lifetime highest weight.

  • Pharmacotherapy of bulimia nervosa and Binge Eating Disorder
    Addictive behaviors, 1995
    Co-Authors: B. Timothy Walsh, Michael J. Devlin
    Abstract:

    This paper reviews the use of medication in the treatment of bulimia nervosa and of Binge Eating Disorder. There is now compelling evidence from double blind, placebo-controlled studies that antidepressant medication is useful in the treatment of bulimia nervosa. What is less clear is which patients are most likely to benefit from antidepressant medications and how to best sequence the various therapeutic interventions available. The utility of antidepressant medications in bulimia nervosa has led to their evaluation in Binge Eating Disorder. The limited information currently available suggests that antidepressant treatment may be associated with a reduction in Binge frequency in obese patients with Binge Eating Disorder, but does not lead to weight reduction. Additional studies of the use of medication in the treatment of Binge Eating Disorder and of the role of pharmacotherapy in the treatment of bulimia nervosa are needed.

  • Eating behavior in Binge Eating Disorder
    The International journal of eating disorders, 1993
    Co-Authors: A B A Juli Goldfein, B. Timothy Walsh, Michael J. Devlin, L B S Janet Lachaussée, Harry R. Kissileff
    Abstract:

    In order to examine the Eating behavior of individuals with the newly proposed diagnosis, Binge Eating Disorder (BED), standardized meals were served to 20 obese women, 10 with BED and 10 without BED. When asked to Binge eat from a multiple-item array of foods, obese subjects with BED consumed significantly more calories than did obese subjects without BED. Significant differences between the two groups were also found on several of the self-report measures.